MapLight Therapeutics shares surge 29.48% after-hours after Stifel Nicolaus maintains Buy rating and Leerink initiates Outperform.
ByAinvest
Wednesday, Dec 3, 2025 5:28 pm ET1min read
MPLT--
MapLight Therapeutics surged 29.48% in after-hours trading following positive analyst ratings. Stifel Nicolaus analyst Paul Matteis reaffirmed a Buy rating on November 24, maintaining a bullish stance on the stock, while Leerink initiated the stock with an Outperform rating, citing strategic positioning and promising investment potential. The dual analyst endorsements, emphasizing MapLight’s favorable outlook and growth prospects, likely fueled the sharp post-market rally.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet